177 related articles for article (PubMed ID: 35461718)
21. HER2 mediates clinical resistance to the KRAS
Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
[TBL] [Abstract][Full Text] [Related]
22. Sotorasib in KRAS
Paz-Ares L; Mehta B; Wang Y; Obiozor C; Waterhouse D; de Langen AJ
Lancet; 2024 Jan; 403(10422):145-146. PubMed ID: 38218612
[No Abstract] [Full Text] [Related]
23. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
24. KRAS G12C inhibition with sotorasib in metastatic colorectal cancer.
Severi C; Van Cutsem E
Ann Palliat Med; 2022 Aug; 11(8):2792-2795. PubMed ID: 35989651
[No Abstract] [Full Text] [Related]
25. Safety and Intracranial Activity of Adagrasib in Patients With
Bernstein E; Luo J; Wang K; Negrao MV; Jänne PA; Sabari JK
JCO Precis Oncol; 2024 Feb; 8():e2300447. PubMed ID: 38330263
[No Abstract] [Full Text] [Related]
26.
Ceddia S; Landi L; Cappuzzo F
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
[No Abstract] [Full Text] [Related]
27. The promise and peril of KRAS G12C inhibitors.
Moore AR; Malek S
Cancer Cell; 2021 Aug; 39(8):1059-1061. PubMed ID: 34375610
[TBL] [Abstract][Full Text] [Related]
28. ABCB1 limits brain exposure of the KRAS
Loos NHC; Retmana IA; Li W; Martins MLF; Lebre MC; Sparidans RW; Beijnen JH; Schinkel AH
Pharmacol Res; 2022 Apr; 178():106137. PubMed ID: 35192958
[TBL] [Abstract][Full Text] [Related]
29. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
[TBL] [Abstract][Full Text] [Related]
30. Sotorasib: First Approved
De SK
Curr Med Chem; 2023; 30(9):1000-1002. PubMed ID: 36082871
[No Abstract] [Full Text] [Related]
31. Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A Case Report.
Sproat MR; Hofherr ML; Devarakonda S
Clin Lung Cancer; 2022 Sep; 23(6):e339-e341. PubMed ID: 35643747
[No Abstract] [Full Text] [Related]
32. Brain Mural Cells Express CAR T-cell Target.
Cancer Discov; 2020 Dec; 10(12):1781-1782. PubMed ID: 33097477
[TBL] [Abstract][Full Text] [Related]
33. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
34. [Sotorasib treatment in KRAS G12C-mutated non-small cell lung cancer: Experience in the Tours university hospital].
Bessy C; Blin T; Pichon E; Marchand-Adam S; Carmier D
Rev Mal Respir; 2023 Jan; 40(1):17-23. PubMed ID: 36566134
[TBL] [Abstract][Full Text] [Related]
35. Nonclinical Safety Profile of Sotorasib, a KRAS
Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
[TBL] [Abstract][Full Text] [Related]
36. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
[TBL] [Abstract][Full Text] [Related]
37. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
[TBL] [Abstract][Full Text] [Related]
38. Distribution of
Nassar AH; Adib E; Kwiatkowski DJ
N Engl J Med; 2021 Jan; 384(2):185-187. PubMed ID: 33497555
[No Abstract] [Full Text] [Related]
39. The KRYSTAL-1 study of adagrasib - a new trial for KRAS
Murciano-Goroff YR; Lito P
Nat Rev Clin Oncol; 2022 Nov; 19(11):677-678. PubMed ID: 35999291
[No Abstract] [Full Text] [Related]
40. Absorption, Distribution, Metabolism, and Excretion of [
Dahal UP; Rock BM; Rodgers J; Shen X; Wang Z; Wahlstrom JL
Drug Metab Dispos; 2022 May; 50(5):600-612. PubMed ID: 35153196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
